Item 2.02 Results of Operations and Financial Condition

On August 16, 2021, AcelRx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2021 (the "Release"). A copy of the Release is furnished herewith as Exhibit 99.1.

The information contained in this Item 2.02 and in Exhibit 99.1 shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits



Exhibit No.          Description
99.1                   Press Release dated August 16, 2021
104                  Cover Page Interactive Data File (embedded within the Inline
                     XBRL document)



1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses